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Abstract
Loss of glycosaminoglycan (GAG) chains of proteoglycans (PGs) is an early event of osteoarthritis (OA) resulting in cartilage
degradation that has been previously demonstrated in both huma and experimental OA models. However, the mechanism
of GAG loss and the role of xylosyltransferase-I (XT-I) that initiates GAG biosynthesis onto PG molecules in the pathogenic
process of human OA are unknown. In this study, we have characterized XT-I expression and activity together with GAG
synthesis in human OA cartilage obtained from different regions of the same joint, defined as ‘‘normal’’, ‘‘late-stage’’ or
adjacent to ‘‘late-stage’’. The results showed that GAG synthesis and content increased in cartilage from areas flanking OA
lesions compared to cartilage from macroscopically ‘‘normal’’ unaffected regions, while decreased in ‘‘late-stage’’ OA
cartilage lesions. This increase in anabolic state was associated with a marked upregulation of XT-I expression and activity in
cartilage ‘‘next to lesion’’ while a decrease in the ‘‘late-stage’’ OA cartilage. Importantly, XT-I inhibition by shRNA or forced-
expression with a pCMV-XT-I construct correlated with the modulation of GAG anabolism in human cartilage explants. The
observation that XT-I gene expression was down-regulated by IL-1b and up-regulated by TGF-b1 indicates that these
cytokines may play a role in regulating GAG content in human OA. Noteworthy, expression of IL-1b receptor (IL-1R1) was
down-regulated whereas that of TGF-b1 was up-regulated in early OA cartilage. Theses observations may account for
upregulation of XT-I and sustained GAG synthesis prior to the development of cartilage lesions during the pathogenic
process of OA.
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Introduction
Osteoarthritis (OA) is a chronic, progressive, degenerative
disorder of joint characterized by breakdown of articular cartilage
leading to functional failure of the joint. OA is characterized by
progressive loss of extracellular matrix (ECM) proteins, causing
mechanical disruption of the articular cartilage surface, together
with subchondral bone sclerosis and osteophyte formation [1].
One of the earliest changes in OA development is the loss of
matrix proteoglycans (PGs) [2], and studies have monitored loss of
aggrecan, the predominant cartilage PG, which provides cartilage
the characteristic mechanical properties of compressibility and
resilience [3]. Evidence from studies in vitro and in vivo indicates
that interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a)
are the predominant cytokines involved in the initiation and
progression of articular cartilage destruction [4,5]. IL-1b, besides
its catabolic activity, inhibits PG synthesis in cartilage, a process
observed in early stages of OA [4–6]. Notably, loss of PG
anabolism not only participates in alteration of the mechanical
properties of cartilage but may also impair the chondrocyte
metabolism and ability to repair the damage. Indeed, PGs control
diverse cellular and biological activities, including cell prolifera-
tion, migration and differentiation. Numerous studies suggest that
most of the biological activity of PGs is mediated by their
glycosaminoglycan (GAG) chains. In this context, GAG chains
play important roles in growth factor signaling, cellular differen-
tiation, morphogenesis, and pathophysiology [7,8]. Therefore,
alteration in the capacity of OA chondrocytes to restore the
integrity of the cartilage matrix may be due to dysfunction of the
regulatory pathway leading to formation of glycosaminoglycan
chains.
In contrast to catabolism of OA cartilage, the synthesis side of
OA has not received much attention. This is important because
the repair potential of cartilage is gaining more attention as target
for OA treatment. The initial event in response to injury by
chondrocytes is an attempt to repair the damaged matrix by up-
regulation of matrix synthesis including PGs. Proteomics studies
have demonstrated elevated anabolism in OA cartilage associated
with enhanced gene expression and biosynthesis of COL2A1 [9].
However, studies in animal models [10] and analysis of cartilage
samples from OA patients [11,12] indicated that this differential
expression may depend upon the zone of cartilage analyzed in
conjunction with the stage of OA progression. In a previous study
[13] we showed that during the early phases of cartilage repair,
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knee, PG synthesis was increased concomitantly to up-regulation
of gene expression of the xylosyltransfersase I (XT-I) responsible
for the initiation of biosynthesis of the chondroitin sulfate and
heparan sulfate GAG chains of PGs. shRNA inhibition of XT-I
expression during recovery phases prevent cartilage repair
indicating that XT-I play a central role in cartilage repair process
[13]. Human studies relative to this issue, however, are lacking at
present, and such information is essential in furthering our
understanding of cartilage degeneration as well as to stimulate
cartilage repair in OA patients. In this study, we examined the role
of XT-I in OA disease. We found that XT-I regulates GAG
synthesis in human cartilage during early onset and late stage of
OA disease and that expression of XT-I gene is regulated by the
proinflammatory cytokine IL-1b and by the cartilage anabolic
factor TGF-b1. Interestingly, forced expression of this enzyme by
gene transfer in late stage OA cartilage enhanced GAG synthesis
and stimulate cartilage repair. Collectively, our results provide
important insights into regulatory factors driving the changes in
GAG synthesis that occur with the onset and progression of
cartilage degeneration.
Materials and Methods
Human osteoarthritis cartilage samples, histology and
scoring disease severity
Articular cartilage samples (femoral condyles and tibial plateau)
were obtained from eight patients with OA (mean age 6569 yr)
undergoing total knee joint replacement. All OA patients were
examined by a certified rheumatologist and were diagnosed as
having OA, using the criteria of the American College of
Rheumatology for OA [14]. This study was approved by our
local Research Institution review board (Comission de la
Recherche Clinique; registration number UF 9757 – CPRC
2004 – Cellules souches et chondroge ´ne `se). The protocol conforms
to the ethical guidelines of the Declaration of Helsinki and written
informed consent has been obtained from each patient. Cartilage
specimens (within 1 h of operation) were dissected using sterile
techniques, and full-thickness cartilage was removed from all of the
femoral condyle using a 6 mm biopsy punch. Extreme care was
taken to avoid subchondral bone, osteophytic cartilage and
fibrocartilage.
Cartilage samples were fixed for 24 h in 4% paraformaldehyde
at 4uC, rinsed in running tap water for 1 minute, decalcified with
RDO (Apex Engineering Products Corporation), in a volume of
decalcifier equal to at least 10-times the tissue volume for 2 h.
Samples were checked every 30 min and decalcified tissue was
rinsed in running tap water for 5 min and further fixed in 4%
paraformaldehyde. Samples were embedded in paraffin, and tissue
sections (5 mm thick) were cut. Histological sections were
rehydrated in a graded series of ethanol and stained with toluidine
blue. Cartilage sections were graded histologically in line with
Mankin’s histological grading system for OA cartilages [15] to
assess disease severity and cartilage damage based on surface
fibrillation, matrix depletion and cellularity, and the integrity of
the tidemark. No tidemarks were present in our cartilage samples.
Construction of XT-I expression vector, transfection of
chondrocyte and GAG synthesis
A human XT-I cDNA has been cloned and ligated into the
unique HindIII-NotI sites of mammalian expression vector pCMV
(Clontech, Mountain View, CA, USA) to generate pCMV-XT-I.
Primary chondrocytes were isolated by sequential enzymatic
digestion with pronase and collagenase of human femoral condyle
cartilage [16] and maintained in DMEM-F12 mix medium in 6-
well plates at 37uC in a humidified atmosphere supplemented with
5% CO2. Cells were then transfected with 1 mg of pCMV-XT-I
expressing vector or pCMV empty vector at 80% confluence using
Exgen 500 (Euromedex, Souffelweyersheim, France). At 48 h
posttransfection, cells were labeled with 10 mCi/ml
35S-sulfate for
the last 6 h of experimental period and PGs were extracted from
cell layer and culture medium [17] with 4 M guanidine
hydrochloride, precipitated using cetylpyridinium chloride, and
sulfated GAG synthesis rate was measured by liquid scintillation
counting [18].
Real-time Quantitative PCR
All reagents and instruments used for RNA extraction were
RNase-free. Total RNA from human cartilage samples was
extracted by homogenization in Trizol solution and purified based
on the manufacturer’s instruction for the RNAeasy Kit (Qiagen,
Cologne, Germany). Briefly, sterile scalpel was used for slicing of
cartilage samples on ice to very small pieces (1 mm pieces) before
homogenization process. Homogenization was performed in a
1.5 ml microcentrifuge tube on ice using a power homogenizer
(Yellowline, DI25) with homogenization time of 10 s intervals for
up to 1 min. The ratio of cartilage to Trizol used was 2% (w/v). In
the case of cultured chondrocytes total RNA was prepared using
RNAeasy kit. cDNA was synthesized from 0.2–1 mg of total RNA
using oligodT primer and Power Script Reverse Transcriptase
(Clontech). Quantitative PCR was performed using LightCycler
system (Roche, Mannheim, Germany) and SYBR green detector
(QIAGEN GmbH, Hilden, Germany). Transcripts were normal-
ized to ribosomal protein S29. RT
2 PCR primer sets for human
XT-I, Aggrecan, IL-1R1, TGF-b1 and ribosomal protein S29
were from SuperArray (Frederick, MD, USA). PCR cycling
parameters were 15 min at 95uC; 40 cycles of 10 s at 95uC, 35 s at
65uC, and 15 s at 72uC. Expression levels of target genes were
normalized to ribosomal protein S29 RNA level.
XT-I shRNA Transfection
Four shRNA vectors for XT-I and control were obtained from
(SuperArray). The shRNA vectors were generated by ligating the
hairpin oligonucleotides of the target sequences A:
CCGGAGGTTTGTAGAATATGT, B: CGGGACAATG-
CAAGGTTCATT, C: GAGAGGCTATTCCGCAACTTT and
D: TACCTTCTTTGCCCGCAAGTT, into SureSilencing
TM
shRNA plasmid. Each vector contains the shRNA under the
control of the U1 promoter. The two vectors expressing shRNA of
the sequences B and D were selected for their ability to
significantly inhibit XT-I gene expression in primary chondro-
cytes. Full thickness cartilage (6 mm-biopsy punch) cultured in
DMEM-F12 medium in 6-well plates at 37uC were transfected
with 5 mg of shRNA-XT-I using the transfection reagent Exgen
500. Total RNA were extracted 72 h after transfection and
expression level of XT-I gene was analyzed by qPCR, as described
below. In parallel, 72 h after shRNA-XT-I transfection, cartilage
explants were pulsed with
35S-sulfate (5 mCi/ml) for the last 6 h
prior to GAG analysis [18].
Cytokine Treatments
Cartilage explants were cultured in six-well plates in DMEM-
F12 medium at 37uC in a humidified atmosphere supplemented
with 5% CO2. After 48 h, explants were serum-starved for 24 h
and treated or not (control) with 10 ng/ml of IL-1b or TGF-b1
(Sigma-Aldrich, Saint Quentin, France) for 24 h. At 6 h before the
end of the treatment, explants were pulsed with
35S-sulfate
(10 mCi/ml) prior to GAG analysis [18].
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synthesis
Full-depth human articular cartilage slices were washed in
serum-free DMEM-F12 medium containing antibiotics, then
diced into 1–2-mm
3 pieces and maintained in a 24-well culture
plate (20–30 mg cartilage/well) in 900 ml of DMEM-F12 and
100 ml of PBS, containing 0.1% (w/v) BSA. After 48 h of
equilibration, explants were radiolabeled with 10 mCi/ml
35S-
sulfate (Perkin Elmer, Courtabœuf, France) for 6 h. Explants were
then digested in papain and aliquots of
35S-labeled digest were
precipitated by using cetylpyridinium chloride [18], and the
sulfated GAG synthesis rate was measured by liquid scintillation
counting.
Protein extraction and enzymatic activity of XT-I in
human cartilage
In brief, cartilage explants were cryosectioned into 10-mm slices
using a freezing microtome (Microm HM 440 E) at 220uC. Slices
were homogenized using a glass Teflon in cold extraction buffer
(500 mM NaCl, 50 mM HEPES, pH 7.2, containing proteinase
inhibitor cocktail) at a ratio of 10:1 (buffer:tissue) on ice [19].
Protein extraction was carried out at 4uC overnight. The resulting
mixture was clarified by centrifugation at 3,000 rpm for 5 min at
4uC. The supernatant was used for measurement of XT-I activity
based on the binding of [
14C]xylose to recombinant bikunin
(acceptor substrate), as reported by Weilke et al [20].
GAG chain analyses by fluorophore-assisted
carbohydrate electrophoresis (FACE)
Disaccharide composition of chondroitin sulfate chain was
examined on proteinase K-digested cartilage explants by FACE
method as described previously [21]. Aliquots containing 5 mgo f
GAGs, as judged from uronic acid assay [22] from each cartilage
sample, were digested with chondroitinase ABC and the
disaccharides obtained were fluorotagged and derivatized [21].
Electrophoresis was carried out at 4uC by using miniature vertical
slab gels of 29% acrylamide and 1% bisacrylamide at 5 W of
constant power per gel. Fluorescent bands were immediately
scanned in a UV-light box Gel Doc System (Bio-Rad, Marne la
Coquette, France) and quantitated with Bio-Rad QUANTITY
ONE software. CS disaccharide standards were from Dextra
Laboratories (Reading, U.K.).
Western blot analysis
Total protein from chondrocytes transfected with pCMV-XT-I
or pCMV empty vector was extracted 24 h posttransfection and
quantified using Bradford method [23]. Proteins (30 mg/lane) were
separated on 12% SDS-PAGE, transferred onto ImmobilonH
(Millipore, Molsheim, France) membrane and then probed with
anti-XT-I antibody (Sigma).
Statistical analysis
Since OA is a focal disease and because of the reported
variations in composition and bioactivity of the cartilage
depending on the site studied, the findings of 3 cartilage samples
per parameter per joint per patient were averaged and considered
as a representative value of that subject [24]. Differences between
cartilage samples taken from the lesion, from sites adjacent to the
lesion, and from sites distant from the lesion were analyzed by
Student’s t-test (within individual knees) and by Wilcoxon’s
matched pairs test (between groups) with values of p,0.05 were
considered significant.
Results
Characterization of lesional and non-lesional areas of
human OA cartilage
Previous studies of human OA have compared late OA cartilage
obtained from joint replacement surgeries to non-OA cartilage
from trauma subjects or at autopsy. However, these samples may
be collected from subjects that are not corresponding according to
age, genetic background or other features, including clinical
management of the disease [25]. Also, it is well known that the
pattern of disease progression clinically may differ from one
patient to another. An alternative method is to evaluate lesional
and non-lesional cartilage from neighbouring areas of the same
joint [25–27]. Three tissue subgroups were objectively segregated
according to their degree of degeneration in the same joint. To
assess disease severity and cartilage damage part of the cartilage
biopsy was processed for histology and graded according to
Mankin’s scale [15] (surface fibrillation, matrix depletion,
cellularity, and the integrity of the tidemark) with a maximum
score of 11. No tidemarks were present in our cartilage samples.
Cartilage samples taken from degenerative lesions were designated
‘‘late disease’’ (grade 8–11). The sample taken from sites
immediately adjacent to lesions was designated ‘‘early disease’’
(grade 3–7) and sample isolated from macroscopically unaffected
region and remote from the lesion was termed ‘‘normal’’ (grade 1–
2). Cartilage was taken from the same topographical region of the
medial condyle and a representative sample of these tissue groups
is illustrated in Fig. 1.
Adaptive increases in sulfated-GAG synthesis in human
early OA cartilage
There was a significant increase (1.5- to 3.5-fold) in the rate of
sulfated-GAG synthesis in cartilage samples recovered near the site
of the lesion (early disease) compared to the samples taken from
Figure 1. Representative sample of femoral condyle from
human OA knee and toluidine blue stained sections. (A) Femoral
condyle from human OA knee joint indicating three sites biopsied for
further biochemical and molecular analysis; (a) cartilage sample taken
from macroscopically unaffected area and distant from the lesion was
termed ‘‘normal’’ (b) cartilage sample isolated from areas immediately
close to lesion was termed ‘‘Next to lesion’’; (c) cartilage specimen
excised from lesion was termed ‘‘late-stage OA’’; Cartilage samples were
isolated using a 6 mm-biopsy punch. (B) Representative photomicro-
graphs of cartilage sections showing areas from where samples were
recovered for toluidine blue staining; (a) cartilage section from a normal
area showing a relatively smooth articular surface; (b) section from
areas close to lesion showing dense staining for PGs in mid zone of the
cartilage where chondrocyte proliferation and activation occurs; (c)
cartilage section from lesions showing degraded articular surface, loss
of PG staining and chondrocyte cloning (original magnification 640).
doi:10.1371/journal.pone.0034020.g001
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analyzed (Fig. 2A and insert), suggesting the hypermetabolic
activity next to degenerated tissue. In contrast, our results
indicated that the rate of sulfated-GAG synthesis was significantly
reduced (1.2- to 3.9-fold) in late OA cartilage (Fig. 2A and insert),
suggesting that it was less active in terms of sulfated-GAG
synthesis. As illustrated in Fig. 1, staining for toluidine blue was
also less evident in late OA cartilage section (compare a to b and
c). Noteworthy, variations in the rate of GAG anabolism was
observed in cartilage from normal areas among the patients
studied indicating inter-individual variations in cartilage metabo-
lism (Fig. 2A).
Gene expression patterns of XT-I and aggrecan define
the pathologic state of the disease in OA cartilage
To determine if the differences observed in sulfated-GAG
synthesis in human OA cartilage were associated with differences
in the expression of XT-I responsible for initiation of chondroitin
sulfate and heparan sulfate GAG synthesis, we performed qPCR
analysis in cartilage samples obtained from areas of ‘‘normal’’,
early disease, and late disease. Depending upon the severity of the
lesions, alterations in expression pattern of XT-I gene was
observed between diseased and normal areas. Striking increases
(1.74- to 8-fold) in the expression level of XT-I gene in OA
cartilage were seen in the regions next to lesion compared to
normal (Fig. 2B and insert). However, in late-stage OA regions,
levels of XT-I expression were significantly lower (1.5- to 7-fold)
compared to normal (Fig. 2B and insert). Thus, XT-I downreg-
ulation in diseased cartilage may be one of the major determinants
of sulfated GAG depletion and disease progression.
Furthermore, our results also showed that the alterations in
aggrecan gene expression paralleled that of XT-I expression with
an increase of 2- to 8-fold in regions next to lesion and a decrease
of 1.5- to 7-fold in late-stage OA areas (Fig. 2C and insert).
Disease-associated alterations in XT activity in human OA
cartilage
As shown in Fig. 3A, the xylosyltransferase activity in cartilage
from three representative OA patients was increased by 1.2- to
2.5-fold in samples from regions next to lesion when compared
with samples from normal regions. In contrast, the activity was
decreased by 1.5- to 4-fold in late-stage OA cartilage samples
compared with cartilage from normal areas. These results clearly
demonstrate that changes in sulfated-GAG synthesis are related to
the expression and enzymatic activity of XT-I and to the severity
of cartilage lesion.
FACE analyses of chondroitin sulfate in human OA
cartilage
Analysis of the fine structure and disaccharide composition of
CS-GAG chains in human cartilage by FACE demonstrated the
presence of unsaturated monosulfated (Ddi6S and Ddi4S) and
nonsulfated (DDi0S) disaccharides from CS/DS chains in normal
cartilage. Next, FACE results suggested that 6-sulfated disaccha-
rides were abundant in adult human cartilage. While it is likely
that disulfated and higher sulfated products might have been
present in the CS-GAG chains, we were unable to profile such
units under our assay conditions. Furthermore this study revealed
a disease-related quantitative variation of CS disaccharides
(Fig. 3B). Notably, a strong increase (80%) in disaccharides
content occurs in cartilage from regions next to lesion, when
compared to normal regions. In contrast, disaccharides content
was dramatically reduced (2.5-fold) in tissue obtained from late-
stage OA areas (Fig. 3B). Thus, it seems very likely that altered
gene expression and activity of XT-I might explain the changes
observed in CS content in cartilage from areas next to lesion and
Figure 2. Analysis of GAG synthesis and expression of XT-I and
aggrecan genes. (A) GAG synthesis analysis in cartilage from
‘‘normal’’, early OA and late-stage OA areas for each patient studied
by
35S-sulfate incorporation. Insert shows the mean of GAG synthesis
rate values corresponding to different areas of cartilage sample from all
patients. Values are mean 6 SEM of 3 experiments per parameter, per
joint, per patient. (B) and (C) Analyses of the expression of XT-I and
aggrecan genes in cartilage from normal, early OA and late-stage OA
areas for each patient. The expression level of the genes was analyzed
by qPCR. Measurements were normalized to the control ‘‘normal’’.
Inserts in (B) and (C) show the mean of XT-I and aggrecan gene
expression level values corresponding to different areas of cartilage
sample from all patients. Values are mean 6 SD of 3 experiments per
parameter, per joint, per patient. **significantly (P,0.01) higher than
normal and late groups; 1significantly (P,0.05) higher than normal and
late groups; *significantly (P,0.05) lower than normal.
doi:10.1371/journal.pone.0034020.g002
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the expression of this glycosyltransferase and sulfated-GAG
content in human OA cartilage.
Down-regulation of XT-I expression impairs sulfated-GAG
synthesis in cartilage
To determine the importance of XT-I in synthesis of sulfated-
GAG in cartilage shRNA was used to transfect chondrocytes and
cartilage explants. Quantitative PCR analyses indicated a down-
regulation of XT-I mRNA expression of about 70% in shRNA-
transfected chondrocytes compared to control groups (Fig. 4A).
Interestingly, analysis of sulfated-GAG anabolism at 72 h post-
transfection showed a reduction of about 50% in shRNA-
transfected chondrocytes compared to control groups (Fig. 4B)
indicating that XT-I plays an important role in sulfated GAG
synthesis in chondrocytes. Similarly, transfection of cartilage
explants from three different patients with shRNA led to a
decrease of sulfated GAG synthesis ranging from 30% to 58%
whereas no inhibition was seen in cartilage explants non-
transfected or transfected with shRNA control (Fig. 4C). Altogeth-
er, these results demonstrated the key role of XT-I in sulfated
GAG synthesis in human cartilage.
Gene delivery of XT-I in chondrocytes and cartilage
explants stimulates GAG synthesis
To directly determine the role of XT-I in cartilage GAG
anabolism, we overexpressed XT-I in human chondrocytes and
cartilage explants. We observed high expression of recombinant
XT-I protein in chondrocytes at 48 h after transfection (Fig. 5A).
Figure 3. Analysis of xylosyltransferase activity and GAG chain
composition. (A) xylosyltransferase activity from normal, early OA and
late-stage OA cartilage of three representative patients. Data are mean
6 SD of 3 experiments per parameter, per joint, per patient.
**Significantly (P,0.01) higher than all groups; *significantly (P,0.01)
higher than normal and late groups;
1significantly (P,0.05) lower than
normal. (B) GAG chain composition in human cartilage explants as
determined by FACE. Proteinase K-digested cartilage explants contain-
ing equal amounts (5 mg) of GAGs, as determined by uronic acid assay
from each group, were digested with chondroitinase ABC and the
disaccharides obtained were fluorotagged and derivatized. Disaccha-
rides were run on a monocomposition gel and gels are representative
images from 3 experiments per parameter, per joint, per patient.
Markers are DDi0S, nonsulfated chondroitin-unsaturated disaccharide;
DDi4S, chondroitin-4-sulfated unsaturated disaccharide; DDi6S, chon-
droitin-6-sulfated unsaturated disaccharide.
doi:10.1371/journal.pone.0034020.g003
Figure 4. Analysis of the effect of XT-I knockdown on GAG
synthesis in chondrocytes and cartilage explants. Cells were
transfected with XT-I shRNA, or control shRNA or left untreated and
then examined for mRNA expression (A) and GAG synthesis (B). Total
RNA was isolated from cells of each group at 72 h posttransfection and
XT-I expression level was determined by qPCR analysis. XT-I mRNA
levels are represented as a ratio relative to those in negative controls or
untreated controls. GAG synthesis was studied by
35S-sulfate incorpo-
ration. (C) Cartilage explants from normal region of human femoral
condyle of three patients were transfected with XT-I shRNA or control
shRNA and then GAG synthesis was analyzed by
35S-sulfate incorpo-
ration. Measurements were normalized to control shRNA. Data
represent the mean 6 SD of 3 independent observations for each
group. **,*Significantly (P,0.01, P,0.05, respectively) lower than
control shRNA.
doi:10.1371/journal.pone.0034020.g004
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fold increase of
35S-sulfate incorporation in XT-I-transfected
chondrocytes compared to empty vector-transfected cells (Fig. 5B)
indicating that overexpression of XT-I significantly enhanced
sulfated GAG synthesis in chondrocytes (probably by increasing
the number of GAG chains that are initiated on a core protein).
These results suggested that XT-I enzyme catalyzes a rate-limiting
step in sulfated GAG synthesis pathway. Interestingly, transfection
of cartilage explants from different patient with pCMV-XT-I
vector produced a 2- to 3.5-fold increase in sulfated GAG synthesis
compared to control (Fig. 5C). These results collectively show that
XT-I regulates GAG anabolism in cartilage.
Expression of IL-1b receptor was down-regulated while
TGF-b1 was up-regulated in early OA cartilage
To determine the link between alteration of XT-I expression
and the pathologic state of the disease in OA cartilage potential
molecular mechanisms involved were investigated. Proinflamma-
tory cytokine IL-1b and growth factor TGF-b1 regulate GAG
anabolism and expression of various factors in chondrocytes.
Indeed, treatment of cartilage explants with IL-1b reduced GAG
anabolism by about 70% (Fig. 6A). In contrast, TGF-b1 treatment
led to an increase of GAG synthesis of about 2-fold (Fig. 6B).
FACE analysis confirmed that TGF-b1 stimulated cartilage CS-
GAG synthesis whereas IL-1b treatment inhibited this process
(Fig. 6C). Interestingly, gene expression analysis indicated
significant downregulation of IL-1b receptor (IL-1R1) (3-fold) in
early OA cartilage compared to late-stage OA cartilage (Fig. 7).
This was associated with an increase of about 2.5-fold in the
expression of the anabolic factor TGF-b1, respectively (Fig. 7).
These results suggested that cartilage next to lesion not only
triggers a mechanism counteracting the effect IL-1b but also
stimulates the anabolic activity of chondrocytes by inducing the
expression of TGF-b1.
Figure 5. Effect of XT-I overexpression on GAG anabolism in
chondrocytes and cartilage. (A) Immunoblot of XT-I protein in
pCMV- or pCMV-XT-I-transfected chondrocytes 48 h after transfection.
XT-I recombinant protein was indicated by the arrow. (B) GAG synthesis
in primary human chondrocytes or (C) in cartilage explants from late OA
region of human femoral condyle transfected with pCMV- (control) or
pCMV-XT-I vector. XT-I- or mock-transfected cells or cartilage were
labeled with
35S-sulfate, and the amount of
35S-labeled GAGs was
measured 48 h posttransfection. Data are mean 6 SD of 3 experiments
per parameter, per joint, per patient. **,*Significantly (P,0.01, P,0.05,
respectively) higher than controls.
doi:10.1371/journal.pone.0034020.g005
Figure 6. Analysis of the effect of IL-1b and TGF-b1 on GAG
synthesis and GAG chain composition. Cartilage explants from
normal regions of human femoral condyle were exposed to IL-1b (A) or
TGF-b1 (B) for 24 h and then GAG synthesis was measured by
35S-
sulfate incorporation. Measurements were normalized to control (non
treated). Data are mean 6 SD of 3 experiments per parameter, per joint,
per patient. **Significantly (P,0.0018) lower than controls;
$significantly
(P,0.05) higher than controls. (C) Effect of IL-1b and TGF-b1 on GAG
chain composition in human cartilage. Cartilage samples derived from
normal regions of human femoral condyle were treated with cytokines
for 12 h and analyzed by FACE. Gels are representative images from 3
experiments per parameter, per joint, per patient. Markers are DDi0S,
nonsulfated chondroitin-unsaturated disaccharide; DDi4S, chondroitin-
4-sulfated unsaturated disaccharide; DDi6S, chondroitin-6-sulfated
unsaturated disaccharide.
doi:10.1371/journal.pone.0034020.g006
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cartilage
Beside its ability to induce degradation of articular cartilage, the
proinflammatory cytokine IL-1b has been shown to suppress the
synthesis of PGs by chondrocytes [28,29]. In contrast the growth
factor TGF-b1 is a potent inducer of chondrocyte matrix
deposition [30–32]. We investigated whether XT-I gene expres-
sion is regulated by IL-1b and TGF-b1. Cartilage explants were
treated or not with IL-1b and TGF-b1, respectively and XT-I
expression was analyzed using quantitative PCR. Our result
showed that IL-1b down-regulated the expression of XT-I by
about 50% (Fig. 8A). In contrast, TGF-b1 induced the expression
by about 3-fold (Fig. 8B). These results clearly indicated that XT-I
gene expression is regulated by the two main cytokines involved in
cartilage metabolism.
Discussion
Our present findings demonstrate that XT-I is likely an
important factor in the regulation of susceptibility of humans to
cartilage degeneration during OA development and progression.
Recently, we showed that loss of XT-I expression increases
propensity to loss of sulfated-GAG synthesis and deposition,
leading to cartilage destruction in antigen-induced arthritis in rats
[13]. Conversely, interruption with XT-I expression disrupts
cartilage repair in papain-injected knee joints of rats, providing
evidence to date that XT-I plays a key role in replacement of
sulfated-GAGs in joint diseases [13]. In order to get more insights,
we explore whether XT-I is an important player in regulating
sulfated-GAG synthesis and content in human cartilage.
Based on the recognition of wide variation in the degenerative
changes in articular cartilages of OA, the use of grading system
pioneered by Mankin et al [15] provides a critical assessment of
the severity of the OA lesion and the metabolic activity of articular
cartilage in OA. There are numerous studies which attempted to
correlate biosynthesis changes of aggrecan in OA with patholog-
ical findings. The studies reported by Thompson and Oegema
[33] reported a decrease in the content of GAG as the histological
grade of arthritis increased. In addition studies by Rizkalla et al
[34] also reported that in early disease (low grade) there was an
increase in GAG synthesis, whereas in late disease it was
decreased. Interestingly, using cartilage obtained from different
disease areas of femoral condyle from the same OA subject, we
describe here, for the first time, the identification of pathology-
related alterations in the gene expression and activity of XT-I. The
levels of XT-I expression correlated with the severity of
degeneration in OA joints. This finding strongly indicated that
cartilage close to lesion expressed higher levels of XT-I and
increased GAG content, which would explain the high synthesis
and content of GAGs in early stages of degeneration. We also
showed the association of low expression of the XT-I gene in
diseased cartilage where the GAG content was demonstrably
reduced. Thus, loss of XT-I expression may set the stage for
gradual reduction in sulfated-GAG synthesizing ability of
chondrocytes, displaying abnormalities in compensating for the
increased degradation of PG-GAGs during OA development.
Collectively, our present findings allowed us to extract clinically
meaningful information from XT-I gene expression profile and
suggest that the pathologic changes involving PG-GAGs in OA
may relate to the degree of alteration of XT-I expression and
activity.
A striking feature of this study is the upregulation of XT-I gene
expression, which becomes significant in view of the present results
on human studies indicating that mRNA levels of aggrecan core
protein are also increased in early OA. Increased availability of
core protein, in the presence of increased XT-I activity, would be
expected to increase the transfer of xylose onto core protein
acceptor and facilitate the initiation of new CS-GAG chains. This
might explain the increase in sulfated-GAG synthesis observations
and could offer an explanation for the increase in chondrocyte’s
capacity to synthesize CS-GAG in early degeneration in OA.
PG-GAG turnover in the cartilage is regulated by a class of
proinflammatory and anti-inflammatory cytokines [4,5]. The
proinflammatory cytokine IL-1b was found to induce cartilage
loss by reducing PG synthesis [28,29,35] and its effects are
mediated through a high-affinity cell surface IL-1 receptor type I
(IL-1RI) [36–38]. Interestingly, our data showed that IL-1RI gene
expression was down-regulated in cartilage ‘‘next to lesion’’
compared to late-OA cartilage, indicating a mechanism protecting
cartilage against IL-1b-induced effects. In parallel to this
Figure 7. Expression of pro-inflammatory and anti-inflamma-
tory cytokines in human OA cartilage. Total RNA was isolated from
human cartilage samples obtained from early OA and late OA regions
and the expression of target genes were analyzed by qPCR. Target
genes in early OA were compared to late OA and expressed as fold
induction. Values are mean 6 SD of 3 experiments per parameter per
joint per patient.
doi:10.1371/journal.pone.0034020.g007
Figure 8. Effect of IL-1b (A) and TGF-b1 (B) on XT-I gene
expression in normal articular cartilage. Cartilage samples isolated
from normal regions of human femoral condyle was exposed to IL-1b or
TGF-b1 and then XT-I gene expression was analyzed by qPCR.
Measurements were normalized to control (non treated). Each value
represents the mean 6 SD of 3 experiments per parameter per joint per
patient. *Significantly (P,0.05) lower than control group; #significantly
(P,0.01) higher than control group.
doi:10.1371/journal.pone.0034020.g008
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TGF-b1, a potent growth factor for cartilage metabolism [39],
than late-OA cartilage. Accordingly, previous studies reported that
TGF-b1 levels are increased in the first stage of the disease [40].
Although these studies indicated that alterations in PG-GAG
anabolism can be influenced by these cytokines, the molecular
basis for these diverse actions are poorly understood. Along these
lines, our study found that IL-1b may promote cartilage loss by
decreasing the expression of XT-I gene with a concomitant
reduction in sulfated-GAG synthesis and content in cartilage
explants. In this regard, previous studies [41–43], including work
from our laboratory [13] have shown IL-1b to down-regulate
aggrecan core protein, XT-I gene and GAG synthesis in cartilage.
In contrast, TGF-b1 treatment results in activation of XT-I gene
expression followed by increased sulfated-GAG levels in cartilage
explants. Interestingly, regulation of XT-I by TGF-b1 has been
also demonstrated in other cell types such as astrocytes [44] and
cardiac fibroblasts [45]. It can thus be postulated that the anabolic
differences exhibited by IL-1b and TGF-b1 in cartilage explants
could originate from their ability to alter XT-I as well as aggrecan
core protein expression, with obvious antagonistic relationship to
one another in terms of cartilage destruction or repair,
respectively. Based on our data, it seems likely that up-regulation
of XT-I and sulfated-GAG anabolism in cartilage ‘‘next to lesion’’
was a consequence of combined effects of a protective mechanism
against IL-1b and stimulatory effects of TGF-b1.
To unmask the role of XT-I in sulfated-GAG formation and
cartilage homeostasis, we studied the effects of targeted suppres-
sion of XT-I with gene silencing strategy in chondrocytes and
cartilage explants. Our data demonstrates that transfection of
chondrocytes with XT-I shRNA reduced their ability to synthesize
sulfated-GAGs compared to normal controls. We also provide
evidence that cartilage explants in which XT-I expression was
silenced by shRNA synthesized lesser amount of sulfated-GAGs
compared to non-transfected controls. These results confirm our
prediction implicating XT-I as an important enzymatic source of
sulfated-GAG production.
From the clinical perspective, development of a targeted
therapy with potential cartilage reparative properties is highly
significant. Therefore, we wished to determine whether XT-I
overexpression represented a valuable therapeutic option to
stimulate sulfated-GAG synthesis in OA. We found that forced
expression of XT-I strongly upregulated GAG synthesis in
chondrocytes and cartilage explants. These in vitro cell culture
and cartilage explant data can be used to predict the beneficial
effects that XT-I would have on OA chondrocytes. Next, in the
hope of achieving clinical benefit in patients with advance OA
disease, we determined if we could rescue the low sulfated-GAG
synthesis activity of chondrocytes from diseased regions of OA
cartilage with over-expression of the XT-I gene. The results
demonstrated that forced expression of XT-I significantly
improved sulfated-GAG synthesis rate in diseased cartilage. These
novel experiments indicate that when XT-I gene is overexpressed
in humans with OA these individuals may be capable of presenting
increased GAG synthesis activity and provide support in pursuing
the demanding goal of cartilage repair.
Clinical implications and conclusions
Although the patient population examined in this study is not
large, nevertheless, the changes in XT-I gene expression we
perceive could contribute to many of the observed biochemical
characteristics of the disease, particularly for the pathological
changes in CS-GAG synthesis and content. Currently, there are
no effective therapies to stimulate sulfated-GAG synthesis in
cartilage repair, and this deficiency is in part a reflection of a
previous lack of understanding of the mechanisms involved in the
loss of GAG synthesis in arthritic diseases. Our findings reported
here record the protective function of the endogenous XT-I and its
role in the maintenance of cartilage GAG homeostasis. Signifi-
cantly, our results show that the quantitative changes in the
expression and activity of XT-I might dictate the disease-related
variations in sulfated-GAG synthesis and content. Therefore,
pharmacological upregulation of XT-I gene expression along with
aggrecan core protein might be expected to increase the amount of
functional PG being synthesized and have a therapeutic potential
for cartilage repair in OA and also in other degenerative joint
diseases.
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